Xylo Technologies (Xylo Technologies) ROCE % : -56.35% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Xylo Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xylo Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was -56.35%.

Xylo Technologies ROCE % Historical Data

The historical data trend for Xylo Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xylo Technologies ROCE % Chart

Xylo Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-156.71

-38.49

10.98

-13.77

-42.84

Xylo Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-13.91	-13.82	-12.68	-30.53	-56.35

Xylo Technologies ROCE % Calculation

Xylo Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-20.274	/	( ( (97.651 - 37.627)	+	(63.896 - 29.268) )	/ 2 )
	=	-20.274	/	( (60.024	+	34.628)	/ 2 )
	=	-20.274	/	47.326
	=	-42.84 %

Xylo Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-23.786	/	( ( (85.667 - 35.879)	+	(63.896 - 29.268) )	/ 2 )
	=	-23.786	/	( ( 49.788	+	34.628 )	/ 2 )
	=	-23.786	/	42.208
	=	-56.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Xylo Technologies (NAS:XYLO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xylo Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Xylo Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xylo Technologies (Xylo Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xylo Technologies Ltd (NAS:XYLO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2QM0:Germany

Address

10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072

Website

https://www.medigus.com

Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.